Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Menter

Showing results (141-150 of 298) with videos related to

Pageof 30
Sort By:
Archives of Dermatology|December 17, 2003
Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell countsKenneth B Gordon, Akshay K Vaishnaw, John O'Gorman, et al.
Journal of the American Academy of Dermatology|August 2, 2003
Psoriasis treatment 2003 at the new millennium: position paper on behalf of the authorsM Alan Menter, Gerald C Krueger, Steven R Feldman, et al.
Seminars in Cutaneous Medicine and Surgery|April 4, 2018
Treating to Target-A Realistic Goal in Psoriasis?Kenneth B Gordon, April W Armstrong, M Alan Menter, et al.
Journal of Drugs in Dermatology : JDD|August 19, 2016
Aerosol Foam Formulation of Fixed Combination Calcipotriene Plus Betamethasone Dipropionate is Highly Efficacious in Patients With Psoriasis Vulgaris: Pooled Data From Three Randomized Controlled StudiesLinda Stein Gold, Mark Lebwohl, Alan Menter, et al.
Journal of Drugs in Dermatology : JDD|June 3, 2020
Importance of Complete Skin Clearance in Psoriasis as a Treatment Goal: Implications for Patient-Reported OutcomesAndrew Blauvelt, Jashin J Wu, April Armstrong, et al.
Journal of Drugs in Dermatology : JDD|October 15, 2016
Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind StudyAlice Gottlieb, Alan Menter, April Armstrong, et al.
Journal of the American Academy of Dermatology|April 19, 2014
The spectrum of oculocutaneous disease: Part II. Neoplastic and drug-related causes of oculocutaneous diseaseAntoinette Day, Amanda K Abramson, Mahir Patel, et al.
Dermatology and Therapy|August 21, 2020
A Real-World Evaluation of the Long-Term Safety and Efficacy of Infliximab in the Treatment Moderate-to-Severe PsoriasisEmily K Haque, Aaminah Azhar, John Corbett, et al.
Dermatology and Therapy|April 4, 2020
Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available EvidenceJashin J Wu, Joseph F Merola, Steven R Feldman, et al.
Drug Safety|July 19, 2008
Safety of efalizumab therapy in patients with moderate to severe psoriasis: an open-label extension of a phase IIIb trialTiffani Hamilton, Alan Menter, Ivor Caro, et al.
Pageof 30

Showing results (141-150 of 298) with videos related to

Sort By:
Pageof 30
Archives of Dermatology|December 17, 2003
Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell countsKenneth B Gordon, Akshay K Vaishnaw, John O'Gorman, et al.
Journal of the American Academy of Dermatology|August 2, 2003
Psoriasis treatment 2003 at the new millennium: position paper on behalf of the authorsM Alan Menter, Gerald C Krueger, Steven R Feldman, et al.
Seminars in Cutaneous Medicine and Surgery|April 4, 2018
Treating to Target-A Realistic Goal in Psoriasis?Kenneth B Gordon, April W Armstrong, M Alan Menter, et al.
Journal of Drugs in Dermatology : JDD|August 19, 2016
Aerosol Foam Formulation of Fixed Combination Calcipotriene Plus Betamethasone Dipropionate is Highly Efficacious in Patients With Psoriasis Vulgaris: Pooled Data From Three Randomized Controlled StudiesLinda Stein Gold, Mark Lebwohl, Alan Menter, et al.
Journal of Drugs in Dermatology : JDD|June 3, 2020
Importance of Complete Skin Clearance in Psoriasis as a Treatment Goal: Implications for Patient-Reported OutcomesAndrew Blauvelt, Jashin J Wu, April Armstrong, et al.
Journal of Drugs in Dermatology : JDD|October 15, 2016
Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind StudyAlice Gottlieb, Alan Menter, April Armstrong, et al.
Journal of the American Academy of Dermatology|April 19, 2014
The spectrum of oculocutaneous disease: Part II. Neoplastic and drug-related causes of oculocutaneous diseaseAntoinette Day, Amanda K Abramson, Mahir Patel, et al.
Dermatology and Therapy|August 21, 2020
A Real-World Evaluation of the Long-Term Safety and Efficacy of Infliximab in the Treatment Moderate-to-Severe PsoriasisEmily K Haque, Aaminah Azhar, John Corbett, et al.
Dermatology and Therapy|April 4, 2020
Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available EvidenceJashin J Wu, Joseph F Merola, Steven R Feldman, et al.
Drug Safety|July 19, 2008
Safety of efalizumab therapy in patients with moderate to severe psoriasis: an open-label extension of a phase IIIb trialTiffani Hamilton, Alan Menter, Ivor Caro, et al.
Pageof 30